FindTrial
Sign In

ABBV-8E12

DRUG5 trials

Sponsors

AbbVie

Conditions

Alzheimer's DiseasePrimary Tauopathy Corticobasal Degeneration Syndrome (CBD)Progressive Supranuclear PalsyProgressive Supranuclear Palsy (PSP)

Phase 1

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
CompletedNCT03413319
AbbVieProgressive Supranuclear Palsy (PSP)
Start: 2018-04-17End: 2019-11-20Updated: 2019-12-03

Phase 2

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
CompletedNCT02880956
AbbVieAlzheimer's Disease
Start: 2017-01-26End: 2021-07-28Updated: 2022-08-26
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
TerminatedNCT02985879
AbbVieProgressive Supranuclear Palsy
Start: 2016-12-12End: 2019-11-20Updated: 2021-02-03
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
TerminatedNCT03391765
AbbVieProgressive Supranuclear Palsy (PSP)
Start: 2018-01-24End: 2019-12-13Updated: 2021-02-03

Unknown Phase

Expanded Access to ABBV-8E12
NCT03744546
AbbViePrimary Tauopathy Corticobasal Degeneration Syndrome (CBD)
Updated: 2019-08-20

Related Papers

Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials
Alzheimer s & Dementia2026-06-26
Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's disease.
2025-10-01
Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy
Movement Disorders2025-08-303 citations
Assessment of AI‐generated digital twin (DT) methodology on reduction of treatment effect variance and potential clinical trial sample size saving using a Phase 2 trial dataset from patients with Alzheimer’s disease (AD)
Alzheimer s & Dementia2024-12-012 citations
Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
2024-02-2216 citations
Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study
Brain2023-02-02117 citations
Does the <scp>Anti‐Tau</scp> Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? Yes
Movement Disorders Clinical Practice2021-08-072 citations
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
2021-03-01105 citations
Antibody-based immunotherapies for Parkinsonian syndromes
Neural Regeneration Research2019-01-014 citations
O1‐02‐06: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS FOR A 96‐WEEK, MULTIPLE DOSE, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY
Alzheimer s & Dementia2018-07-012 citations
[O2–17–01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO‐CONTROLLED STUDY OF ABBV‐8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE
Alzheimer s & Dementia2017-07-0111 citations